SciCombinator

Discover the most talked about and latest scientific content & concepts.

Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to TNF Antagonists

OPEN Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association | 19 Sep 2016

BG Feagan, DT Rubin, S Danese, S Vermeire, B Abhyankar, S Sankoh, A James and M Smyth
Abstract
The efficacy and safety of vedolizumab, a humanized immunoglobulin G1 monoclonal antibody against the integrin α4β7, was demonstrated in multicenter, phase 3, randomized, placebo-controlled trials in patients with moderately to severely active ulcerative colitis (UC) or Crohn’s disease. We analyzed data from 1 of these trials to determine the effects of vedolizumab therapy in patients with UC, based on past exposure to anti-tumor necrosis factor (TNF) agents.
Tweets*
4
Facebook likes*
2
Reddit*
0
News coverage*
64
Blogs*
0
SC clicks
0
Concepts
Abdominal pain, Monoclonal antibodies, Colitis, Colon, Infliximab, Tumor necrosis factor-alpha, Crohn's disease, Ulcerative colitis
MeSH headings
-
comments powered by Disqus

* Data courtesy of Altmetric.com